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STEAP2 Knockdown Reduces the 
Invasive Potential of Prostate 
Cancer Cells
Stephanie E. A. Burnell1, Samantha Spencer-Harty2, Suzie Howarth3, Owen Bodger  1, 
Howard Kynaston4, Claire Morgan1 & Shareen H. Doak1
Six-transmembrane epithelial antigen of the prostate-2 (STEAP2) expression is increased in prostate 
cancer when compared to normal prostate, suggesting STEAP2 may drive prostate cancer progression. 
This study aimed to establish the functional role of STEAP2 in prostate tumourigenesis and evaluate if 
its knockdown resulted in reduced invasive potential of prostate cancer cells. PC3 and LNCaP cells were 
transfected with STEAP2 siRNA and proliferation, migration, invasion and gene expression analyses 
were performed. STEAP2 immunohistochemistry was applied to assess the protein expression and 
localisation according to Gleason score in 164 prostate cancer patients. Invasion significantly decreased 
in both cell lines following STEAP2 knockdown. PC3 proliferation and migration capacity significantly 
reduced, while LNCaP cell morphology and growth characteristics were altered. Additionally, STEAP2 
downstream targets associated with driving invasion were identified as MMP3, MMP10, MMP13, 
FGFR4, IL1β, KiSS1 and SERPINE1 in PC3 cells and, MMP7 in LNCaP cells, with CD82 altered in both. 
In patient tissues, STEAP2 expression was significantly increased in prostate cancer samples and this 
significantly correlated with Gleason score. These data demonstrate that STEAP2 drives aggressive 
prostate cancer traits by promoting proliferation, migration and invasion and significantly influencing 
the transcriptional profile of ten genes underlying the metastatic cascade.
Prostate cancer (PCa) is the second most common cancer worldwide, with one in eight men being diagnosed in 
the UK and one in five/six in the USA1,2. There is currently no routine PCa screening system, however, accord-
ing to the 2016 American Cancer Society guideline, from the age of 45, men should receive information and be 
allowed to make their own decision regarding screening, but this only occurs if a patient has specific risk factors 
or presents with urinary/sexual symptoms3. Men without symptoms are discouraged from PCa screening by 
the US Preventive Services Task Force due to the risk of detecting slow growing cancers that will not require 
treatment within the patients’ lifetime4. As slow growing cancers cannot be distinguished from fast growing, 
aggressive cancers, new prognostic biomarkers are required to improve patient stratification, assist with clinical 
management of the disease and prevent the overtreatment of PCa patients.
An understanding of many of the key molecules in the invasion and metastasis cascade is currently being 
formed, however, substantial gaps in our knowledge remain5–8. The six-transmembrane epithelial anti-
gen of the prostate (STEAP) family contains four members and shares significant sequence homology 
with FRE metalloreductases in yeast at the C-terminus, and with bacterial and archaeal metalloreductases 
F420:NADPH-oxidoreductases (FNO) and human NADPH-oxidoreductase (NOX) at the N-terminus9,10. The 
N-terminal (apart from STEAP1) also contains a Rossman fold motif, which is thought to be vital for binding 
nucleotides such as flavin adenine dinucleotide (FAD). The six-transmembrane (6TM) domain, a heme-binding 
domain, is present in each protein and is also known as the apoptosis, cancer and redox associated transmem-
brane (ACRATA) domain10. This family is generally localised to the plasma membrane, golgi and trans-golgi 
network11,12. Our current functional understanding of this protein family in mammalian cells is limited; proteins 
containing the 6TM domain often serve as ion channels at cell junctions and due to the significant sequence 
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homology with various metalloreductases, it has been suggested that the STEAP family may play a role in iron 
and copper reduction9,11. STEAP2, 3 and 4 expression has been shown to increase iron and copper uptake and 
promote reduction of iron and copper in vitro9.
A body of literature demonstrates altered STEAP gene expression patterns within several cancers. While this 
information presents the STEAP family members as important targets for a variety of diseases, our studies specif-
ically focus on STEAP2, which appears to be specifically overexpressed in aggressive PCa12–14. We have recently 
described STEAP2 as overexpressed in PCa cells when compared to a normal prostate cell line and this was 
validated in a small pilot cohort of human tissues14. In the present study, we utilised two PCa cell lines, PC3 and 
LNCaP due to the fact they both originate from metastatic tumours and their high STEAP2 protein expression 
levels. The LNCaP cells express STEAP2 to a higher degree when compared to the PC3 cells, although the reason 
for this is, as yet, unknown14. Although both cells lines were originally derived from PCa metastases, they are 
technically distinct. The LNCaP cell line, which was derived from the supraclavicular lymph node by Horoszewicz 
in 1980, has been shown to express both androgen receptor (AR) and prostate specific antigen (PSA) and is 
androgen sensitive due to a mutation in the AR gene allowing it to bind to other steroids15,16. On the other hand, 
PC3 cells which were derived from bone metastases, do not express AR or PSA and do not respond to andro-
gens17. LNCaP cells appear to share common features with adenocarcinomas, the most common diagnosed form 
of PCa; whilst PC3 cells appear to be more characteristic of the more aggressive prostatic small cell neuroendo-
crine carcinoma18. Additionally, while both LNCaP and PC3 cells have been shown to possess similar expression 
of proliferation-associated markers, differences in angiogenic markers, pro-inflammatory cytokines, PCa markers 
and responses to environmental stresses have been observed19. These two cell lines were therefore selected as a 
model to evaluate the functional role of STEAP2 in the development of aggressive cancer traits.
Due to the overexpression of STEAP2, specifically in invasive PCa, we hypothesised that STEAP2 may play an 
integral mechanistic role in progression to advanced disease. Hence, the aim of the present study was to establish 
the functional role of STEAP2 in driving PCa progression and to determine whether reduction of protein expres-
sion, via siRNA treatment, could reverse the tumourigenic impact of this protein.
Results
The aim of this study was to develop an understanding of STEAP2’s role in driving prostate tumourigenesis by 
knocking-down STEAP2 expression (KD) in PC3 and LNCaP cells and analysing the subsequent functional 
changes compared to wild type (WT) and scrambled siRNA treated (Sc) cells as controls. Additionally, STEAP2 
expression and localisation patterns were analysed in 164 PCa samples by IHC and correlation with Gleason score 
was explored.
STEAP2 Knockdown Reduces Proliferative Potential in PC3 Cells. To investigate STEAP2’s role in 
the progression of PCa, expression was knocked down in PCa cell lines, PC3 and LNCaP. STEAP2 gene expres-
sion was knocked down by 97% and 95% in PC3KD and LNCaPKD cells respectively (Fig. 1A and E), this trans-
lated to a 40% and 50% respective reduction in protein levels over the experimental duration (Fig. 1B and F). To 
assess the effect of reducing STEAP2 expression on the proliferation of the PCa cells, iCELLigence analysis was 
carried out. PC3KD cells exhibited a significant reduction (53%, p < 0.001) in the proliferation rate and maximum 
cell number when compared to PC3Sc cells (Fig. 1C and D). Conversely, no significant difference was observed 
between the LNCaPKD and LNCaPSc cells (Fig. 1G and H). To evaluate whether this effect on proliferation was 
due to cell cycle alterations in response to STEAP2 knockdown, cell cycle analysis was carried out on both PC3 
and LNCaP cells treated with STEAP2 siRNA (Figure S1). For PC3 cells, no significant difference in the cell cycle 
profile was noted in response to STEAP2 knockdown, whilst in LNCaPKD cells, a significant decrease in G0/G1 
phase (p = 0.016) and a significant increase in G2/M phase (p = 0.019) was observed. However, as proliferative 
differences only arose in PC3KD cells, this data suggest that an altered cell cycle profile was not subsequently 
responsible for their reduced proliferative capacity.
STEAP2 knockdown Reduces Migratory Potential of PC3, and alters growth characteristics of 
LNCaP Cells. The ability of PC3 and LNCaP cells to migrate following the knock-down of STEAP2 was ana-
lysed using the IBIDI cell culture inserts. Representative images of time points 0, 12 and 24 h for PC3 cells and 
0, 48 and 96 h for LNCaP cells are illustrated in Fig. 2. Both PC3WT and PC3Sc cells had closed the gap within 
24 h following removal of the insert, however, in the PC3KD cells, the gap remained open, demonstrating that 
reduction of STEAP2 expression in the PC3 cell line resulted in decreased migratory potential. LNCaP cells were 
examined over a 96 h period due to their slower and less uniform growth characteristics. The migration observed 
was to the same extent for all cells regardless of transfection status and complete closure was not achieved by the 
end of the 96 h time frame. The images taken of the LNCaP cells were analysed using ImageJ software and movies 
of the cells were generated (Figure S2 and S3). These movies revealed that the LNCaPSc cells move into the gap by 
growing on top of each other, which forces them into the empty space. In contrast, the movement of the LNCaPKD 
cells was less haphazard, with the cells growing in a manner more closely resembling that of less invasive cells with 
contact inhibition, forming a monolayer rather than stacking on top of each other (Fig. 3). The images taken in 
Fig. 3 are the same magnification and time point, further demonstrating the changes in morphology in response 
to STEAP2 knockdown in LNCaP cells. The reduction of STEAP2 expression therefore had a notable conse-
quence on the migration and growth characteristics of both LNCaP and PC3 cells.
STEAP2 Knockdown Reduces Invasive Potential in both PC3 and LNCaP cells. Cancer cells that 
have acquired invasive potential have increased ability to migrate into their surrounding area to establish distant 
metastases. Figure 4A–D illustrates that the invasive potential of PC3KD cells was significantly reduced when 
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compared to the PC3Sc cells (36%, p < 0.001). Similarly, the LNCaPKD cells had a significant 50% reduction of 
invasive potential when compared to the LNCaPSc cells (p < 0.001, Fig. 4E–H). Furthermore, while both the 
LNCaPWT and LNCaPSc cells readily invaded through the membrane in large clusters, LNCaPKD cells were more 
dispersed. This provides further evidence to support the increased contact inhibition exhibited by these cells 
following STEAP2 knockdown.
Figure 1. STEAP2 Knockdown results in a significant reduction in cell proliferation in PC3 cells. (A) qRT-PCR 
analysis for STEAP2 gene expression in control (PC3WT and PC3Sc) and STEAP2-siRNA (PC3KD). (B) Western 
blot analysis for STEAP2 protein expression in control (PC3WT and PC3Sc) and STEAP2-siRNA (PC3KD). 
(Loading control = Β-actin, Black lines represent where the western blot image has been edited for clarity).  
(C) Growth rate of the cells recorded in cell index (CI) values. PC3 cells monitored over a 72 h period and 
PC3KD cells proliferate at a slower rate. (D) The maximum cell index values (i.e. final cell numbers) were 
significantly reduced in the PC3KD cells compared to PC3Sc control (***P < 0.001). (E) qRT-PCR analysis for 
STEAP2 gene expression in control (LNCaPWT and LNCaPSc) and STEAP2-siRNA (LNCaPKD). (F) Western blot 
analysis for STEAP2 protein expression in control (LNCaPWT and LNCaPSc) and STEAP2-siRNA (LNCaPKD). 
(Loading control = Β-actin, Black lines represent where the western blot image has been edited for clarity.)  
(G) LNCaP cells were monitored over a 96 h period and there was no difference observed between transfections. 
(H) The maximum cell index values were not altered in the LNCaPKD cells compared to LNCaPSc control.
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STEAP2 Knockdown Alters Downstream Signalling in both PC3 and LNCaP cells. Gene expres-
sion arrays were utilised to compare the expression changes of genes involved specifically in metastasis and inva-
sion following STEAP2 knockdown. Figure 5 illustrates the results obtained from analysing 84 genes in the PC3 
(A) and LNCAP (B) cells, a significant change was assigned when a ≥2-fold change in expression was recorded, 
Figure 2. Decreasing STEAP2 expression significantly reduced the migratory capacity of the PC3 PCa cells. 
(A) PC3 cells shown as WT, Sc or KD imaged at 0, 12 and 24 h following the removal of the insert. The PC3WT 
and PC3Sc cells successfully closed the gap after 24 h; the gap remained open in the PC3KD cells. (B) LNCaP 
cells shown as WT, Sc or KD imaged at 0, 48 and 96 hours following the removal of the insert. Decreasing the 
expression of STEAP2 in LNCaP cells had no significant effect of the migratory potential of the cells. The gap 
remained open in all samples after 96 h of observation.
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p < 0.05. Genes demonstrating significant alterations in expression profiles in response to STEAP2 knockdown 
are summarised in Table 1. Some alterations in gene expression were only induced in scrambled siRNA treated 
cells, and these were excluded from the results as an artefact of the transfection process (MMP13, FGFR4 and 
MET). qRT-PCR was utilised to validate the original array findings (Table 1). The alterations observed in response 
to STEAP2 knockdown were: MMP3 (5-fold increase), MMP10 (5-fold increase), KISS1 (3-fold increase), 
SERPINE1 (3-fold increase), CD82 (2-fold increase) and IL1β (2-fold decrease) genes in PC3 cells and MMP7 
(2-fold decrease) and CD82 (2-fold decrease) genes in LNCaP cells.
STEAP2 Protein Expression is higher in Patient’s Tumour Tissue than in Matched Normal 
Samples and correlates with Gleason Score. The expression profile and localisation of STEAP2 was 
examined in normal and cancerous prostate specimens and correlation with tumour aggressiveness was evaluated 
by IHC. Representative images of STEAP2 staining in normal prostate and PCa tissue are presented in Fig. 6. 
STEAP2 expression is very low in normal prostate specimens, with only very light staining in the cytoplasm. 
STEAP2 was expressed to a significantly higher level in the PCa specimens when compared to the normal pros-
tate specimens and had primarily nuclear localisation (p < 0.001, Fig. 6G). From Gleason 7(3 + 4 and 4 + 3) the 
intensity of STEAP2 stain increased in a stepwise fashion to Gleason 9/10 and a significant positive correlation 
was observed when STEAP2 score was compared against Gleason scores (r = 0.190, p = 0.049, Fig. 6H). These 
data suggest STEAP2 expression levels alone are not sufficient to distinguish between Gleason scores due to the 
similarities in staining, but that it would be a suitable biomarker to distinguish between normal prostate and PCa 
specimens.
Discussion
The ability to discriminate between patients whose PCa will remain indolent and those that develop aggres-
sive tumours is of great value to support patient risk stratification and aid clinical management of the disease. 
STEAP2 is elevated in PCa tissues, both in vitro and in clinical samples compared to normal prostate cells12,14. To 
determine the functional role of STEAP2 in prostate tumourigenesis, protein expression was reduced in PC3 and 
LNCaP cells and the subsequent impact analysed.
The hypothesis that increased STEAP2 expression results in a phenotype that aids in the progression of PCa 
was assessed by measuring the proliferation, migration and invasion of PC3 and LNCaP cells with reduced 
STEAP2 expression (KD) and comparing them to their wild type (WT) and scrambled siRNA treated (Sc) coun-
terparts. The proliferation assay demonstrated that the growth of PC3KD cells was decreased when compared to 
the PC3Sc cells, supporting Whiteland et al.14; but this was not associated with altered cell cycle distribution. In 
contrast, the proliferative ability of LNCaPKD was not altered, which contradicts the work of Wang et al. who 
showed a significant decrease of proliferation in LNCaPKD cells20. This discrepancy could be due lack of compar-
ison to the wild type or non-transfected LNCaP cells in the Wang et al. study. As demonstrated in the present 
study, the scrambled siRNA induces alterations in the cells that are not present in the wild type cells, therefore 
without this comparison; it is difficult to determine what is causing the alterations. Additionally, due to the high 
level of STEAP2 protein expression in the LNCaP cells and its long half-life; it is possible that the 50% reduction 
Figure 3. Representative images of the spread of LNCaP cells. (A) Scrambled siRNA treated LNCaP cells and 
(B) STEAP2 siRNA treated LNCaP cells. Both images were taken at the same magnification.
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of protein expression observed in the present study had lesser impact on the pathways involved in proliferation. 
Further studies are required where these experiments are conducted on stably transfected LNCaP cells, using 
either shRNA, CRISPR or lentiviral knockdown, resulting in a more permanent reduction of STEAP2 expression.
The migratory potential of PC3KD cells was shown to be significantly reduced when compared to the PC3Sc 
cells, however, not in the LNCaP cells. The LNCaP cells are notoriously difficult to work with due to their reduced 
adherence and tendency to grow in clumps21. It was of interest to note that the growth pattern of the LNCaP cells 
were altered following STEAP2 knockdown. LNCaPSc and LNCaPWT cells grow on top of each other rather than 
into the space created by the insert, which reflects the known growth characteristics of LNCaP cells22. However, 
the LNCaPKD cells grew more readily as a monolayer with less stacking, suggesting that even a slight reduction of 
STEAP2 expression in the LNCaP cells results in partially reinstated contact inhibition, albeit not as profound as 
the effect on the PC3 cells. This observation indicated that STEAP2 may play a substantial role in the migration 
and growth characteristics of both cell lines. In the PC3KD cells, the invasive potential was reduced by approxi-
mately 20%, while in the LNCaPKD this was almost 50%. These data taken together therefore indicate a role for 
STEAP2 in the progression of PCa cells as the ability of the PC3 and LNCaP cells to both migrate and invade were 
altered when STEAP2 expression was reduced.
To further understand the downstream signalling targets influenced by STEAP2, a PCR gene array was uti-
lised to evaluate its impact on 84 genes associated with metastasis. Eight genes were altered in PC3KD cells and 
two in LNCaPKD cells; MMP13, MMP3, MMP10, FGFR4, KISS1, SERPINE1 CD82 and IL1β in the PC3 cells and 
MMP7 and CD82 in LNCaP cells.
MMP3, a member of the matrix metalloproteinase protein family, is involved in wound healing and degrada-
tion of the ECM during tissue remodelling and tumour metastasis23. MMP3 overexpression has been reported in 
PCa as well as breast, lung and pancreatic cancer cells, tissues and mouse models, it is hypothesised to aid inva-
sion and metastasis via degradation of the ECM24–27. It was therefore surprising that STEAP2 knockdown would 
result in a significant up-regulation MMP3. However, one clinical study on prostate tissues has reported a signif-
icantly decreased expression of MMP3 in PCa samples when compared to normal prostate and Benign Prostatic 
Hyperplasia (BPH) samples and this correlated with Gleason score28. Furthermore, most MMPs are produced and 
excreted from the cell in an inactive form, they are then activated extracellularly29. Increased expression may not 
correlate with increased pro-enzyme activation, thus further exploration of this enzyme activity status is required. 
KiSS1 encodes the protein kisspeptin, a G-protein coupled receptor ligand for GPR54 and a metastasis suppressor 
in malignant melanoma and bladder cancer. Expression of KiSS1 is reduced or lost in the more advanced can-
cers30–33. In the present study, reduced STEAP2 expression increases the expression of KiSS1, which suggests an 
inhibition of metastases (supported by the migration and invasion experiments). Thus, the relationship between 
STEAP2 and KiSS1 may be an important signalling pathway responsible for controlling the metastatic potential 
of PCa cells. SERPINE1, which encodes the protein plasminogen activator inhibitor 1 (PAI-1), a serine protease 
inhibitor, was significantly overexpressed in response to STEAP2 knockdown. PAI-1 inhibits tissue plasminogen 
activator (tPA) and Urokinase (uPA), both of which are responsible for the cleavage of plasminogen to plasmin 
which goes on to mediate the degradation of the ECM in combination with MMPs, therefore facilitating invasion 
and metastatic spread34. This indicates an inhibition of invasion, which is supported by the experiments presented 
Figure 4. Decreasing STEAP2 expression significantly reduced the invasive potential of both the PC3 and 
LNCaP cells. Images of stained cells were taken to give a visual representation of invasion each panel represents 
(A) PC3WT, (B) PC3Sc, (C) PC3KD cells and (E) LNCaPWT, (F) LNCaPSc, (G) LNCaPKD cells. (D and H) The 
stain was then extracted from the collagen matrix and the absorbance was measured to quantify the number of 
stained cells for PC3 cells and LNCaP cells respectively. The number of invasive cells was significantly lower in 
both the PC3KD and LNCaPKD cells (***P < 0.001 for both cell lines).
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here, additionally, many studies have shown that PAI-1 prevents invasion of cancer cells by inhibiting uPA pro-
tease activity35. CD82, a tumour suppressor, was significantly overexpressed in the PC3KD cells, but significantly 
decreased in LNCaPKD cells. CD82 has been reported to be significantly overexpressed in BPH associated with 
cancer when compared to BPH not linked to cancer and thus CD82 overexpression may restrict PCa development 
while its loss may predispose the patient to more aggressive disease36. This therefore suggests that overexpression 
of STEAP2 and loss of CD82 both lead to aggressive PCa. The only down-regulation in PC3KD cells was IL1β, 
an inflammatory cytokine important in mediating immune responses. IL1β plays an important role in the pro-
gression of PCa37,38. Recently, Liu et al. showed that IL1β was overexpressed in PCa and correlated with Gleason 
score38. Further to this, the group also demonstrated that overexpression of IL1β in non-metastatic PCa cells 
promoted their growth in the bone, while knockdown in metastatic cells inhibited bone progression, which is a 
particularly important observation given the down regulation noted here in PC3KD cells38.
In the LNCaPKD cells MMP7 was significantly decreased when compared to the LNCaPSc cells. MMP7 is the 
smallest MMP family member and is overexpressed in many cancers including those of the bladder, colorec-
tal, gastric and pancreatic39. Expression of MMP7 in mice promotes tumour development whereas reduction 
of MMP7 expression diminishes tumour incidence, although the exact mechanism is yet to be defined40,41. This 
protein is associated with increasing the invasive potential of cancer both in vitro and in vivo and is therefore 
important in the progression of aggressive disease39. This theory is supported by observations in the present study 
where a significant reduction of MMP7 expression in response to STEAP2 knockdown was also associated with 
reduced invasive capacity of the LNCaPKD cells.
Figure 5. Normalised Expression of Tumour Metastasis Gene Array. The scatter plots were derived from 
comparison of the Scrambled siRNA treated cells (labelled as control) against the STEAP2-siRNA treated group 
(KD) in (A) PC3 cells or (B) LNCaP cells. The graphs show the number of up- and down-regulated genes in 
response to treatment depicted in yellow and red respectively.
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There was a much more pronounced effect on the expression of genes involved in the tumour metastasis path-
way in the PC3KD cells than the LNCaPKD cells and there were no matched gene expression changes in the two 
cell lines. This is unsurprising given the different tissue origins of these cell lines and that their expression profiles 
represent two distinct PCa cell lineages19. The protein expression of STEAP2 in LNCaP cells is higher than in PC3 
cells; given that a similar percentage of protein knockdown were achieved in both cell lines, the absolute levels of 
STEAP2 in the LNCaP cells following knockdown were therefore higher than in PC3, which could account for the 
greater transcriptional change noted in PC3 cells. Nonetheless, the reduction of STEAP2 protein expression has 
led to similar phenotypic changes in both cell lines; namely alterations in migration and a reduction in the inva-
sive potential. This suggests that STEAP2 plays a significant role in such processes that are important in driving 
the development of aggressive PCa.
To support the functional cell analysis, the expression profile of STEAP2 in PCa was evaluated using IHC. This 
demonstrated a significant difference in STEAP2 staining intensity between normal prostate and PCa specimens, 
with a significant positive correlation between STEAP2 intensity and Gleason score. These data correspond with 
previous studies that have shown a significant increase of STEAP2 expression in cancer compared to normal sam-
ples in smaller patient cohorts12,14. One study on a small cohort of patients was unable to find such an association 
between the expression of STEAP2 in PCa tissue samples and Gleason scores, but it is possible that this was due 
to the limited patient cohort size20. Additionally, the spread of specimens is unknown as the author states that the 
samples were either < Gleason 7 (n = 22) or ≥ Gleason 7 (n = 45). Although a significant correlation was noted 
in the present study, it remains that the ANOVA analysis recorded no significant differences between groups. A 
larger patient cohort may assist in more clearly defining these differences, but nonetheless the present study pre-
sents a promising case for STEAP2 as a supporting prognostic biomarker for aggressive PCa.
This investigation has demonstrated that reducing STEAP2 expression in PCa cells significantly reduces their 
ability to proliferate, migrate and invade into their local surroundings. Although no significant difference in 
proliferation was observed in LNCaP cells in response to STEAP2 knockdown, a distinct difference in migratory 
behaviour, along with a significant reduction in invasive potential was observed in the LNCaPKD cells, indicating 
that STEAP2 may be an interesting potential drug target in the future. Further to the in vitro study, STEAP2 
expression and localisation were examined in a cohort of 164 PCa tissues; STEAP2 expression was increased in 
tumour tissue when compared to normal tissue and this significantly correlated with Gleason score. This gives 
rise to the possibility of utilising STEAP2 as a prognostic tool to determine the potential of PCa to progress to 
advanced disease.
Methods
Cell Culture. Authenticated PC3 and LNCaP cells purchased from American Type Culture Collection (ATCC, 
LGC Standard) were maintained in RPMI 1640 media (Gibco, Life Technologies, UK) supplemented with 10% 
fetal bovine serum (FBS), 2 mM glutamine, and 100 U/ml penicillin/streptomycin (Gibco, Life Technologies, UK) 
at 37 °C and 5% CO2.
siRNA Transfection. STEAP2 expression was reduced using siRNA S48991, a non-specific siRNA (4390843) 
was used as a control (Life Technologies, UK) and Lipofectamine RNAiMAX (Life Technologies, UK) was used 
according to manufacturer’s instructions. PC3 cells were incubated with the siRNA complex for 72 h. LNCaP cells 
were reverse transfected with the siRNA complex for 120 h.
Western Blot. Protein was extracted from PC3 and LNCaP cells using RIPA buffer (Sigma, UK) supple-
mented with protease inhibitor cocktail (1%, Sigma, UK). Protein (30 µg) was resolved using 10% sodium dode-
cyl sulphate polyacrylamide gel electrophoresis gels at 120 V for 90 minutes and transferred to polyvinylidene 
fluoride (PVDF) membrane at 400 mA for 90 minutes at 4 °C. Membranes were blocked using 5% milk in Tris 
Buffered Saline plus 1% Tween 20 (TBST) and incubated with STEAP2 antibody (1:1000, rabbit IgG, polyclonal, 
Gene
Relative Change in Expression 
(according to gene array)
qRT-PCR data 
for WT cells
qRT-PCR data 
for KD cells
PC3
FGFR4 2.65 2.518* 3.283*
IL1β −3.64 0.917 0.564*
KiSS1 2.79 1.699* 3.198*
CD82 2.74 1.647* 2.695*
MMP3 2.16 0.864 5.369*
MMP10 4.47 2.739* 4.947*
MMP13 4.19 4.781* 5.587*
SERPINE1 2.70 1.421* 3.191*
LNCaP
CD82 −2.21 0.756 0.478*
IGF1 −2.60 1.174 0.993
MMP7 −4.82 0.881 0.434
MET 4.79 3.523* 4.471
Table 1. Quantitative Real Time PCR Analysis of Array Results. qRT-PCR was carried out on genes detected 
as altered in the tumour metastasis gene array and analysed in triplicate. Relative expression is depicted 
normalised to scrambled siRNA treated cells. Significant alterations *p < 0.05.
www.nature.com/scientificreports/
9SCientifiC RepoRts |  (2018) 8:6252  | DOI:10.1038/s41598-018-24655-x
Sigma, UK) or β-actin antibody (1:1000, rabbit IgG, monoclonal, Cell Signalling, UK) overnight at 4 °C, antibod-
ies were prepared in blocking buffer. Secondary antibodies (1:1000, Anti-rabbit IgG, Abcam, UK) were applied 
for 1 hour at room temperature. Images of the bands were visualised using Enhanced Chemiluminescence (ECL) 
reagent (Thermoscientific, UK).
Quantitative Real Time PCR (qRT-PCR). Total RNA was extracted from cells using the RNeasy extraction 
kit (Qiagen) following manufacturers instructions. cDNA was prepared using Retroscript reverse transcription 
Figure 6. STEAP2 expression is higher in PCa specimens when compared to normal prostate tissue and 
increases with Gleason score. STEAP2 staining intensity was observed in (A) Normal patient samples and 
compared to (B) Gleason 6, (C) Gleason 7 (3 + 4), (D) Gleason 7 (4 + 3), (E) Gleason 8 and (F) Gleason 9/10. 
Staining intensity increased from normal to cancer samples and increased in a stepwise fashion from Gleason 6 
to Gleason 9/10. (G) Significant difference in STEAP2 score observed between normal and cancer patients.  
(H) A significant positive correlation (r = 0.190) between Gleason score and STEAP2 score was determined 
using a Pearson correlation test. Significance denoted as ***p < 0.001.
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kit (Ambion, Thermoscientific) according to manufacturer’s instructions. Pre-validated STEAP2 primers 
(NM_152999), along with primers for two housekeeping genes, β-actin (NM_001101) and Beta-2 microglobulin 
(B2M) (NM_004048), plus 2x precisionPLUS mastermix were obtained from PrimerDesign and qRT-PCR was 
carried out following the manufacturer’s instructions.
Functional Assays. Proliferation. Experiments were carried out using the iCELLigence (ACEA Bioscience) 
according to the manufacturer’s instructions. Impedance was measured every minute for the first 2 h, then every 
hour for 72 h and displayed as arbitrary cell index (CI) values which represent the electrical impedance that 
results from proliferation (n = 3).
Cell Cycle. Cells were treated with SYTOX green (LitronLabs, USA) according to manufacturer’s instructions. 
As a positive control, cells were treated with 7.5 µM methyl methanesulfonate (MMS) for 23 hours to induce a G2 
block. Samples were run using the BD FACS Aria flow cytometer (BD Biosciences, USA) (n = 3).
Migration. WT, SC and KD PC3 and LNCaP cells were seeded into the wells of the IBIDI cell culture inserts 
(IBIDI, Germany) and adhered for 24 h (PC3) or 48 h (LNCaP). Media and inserts were removed following incu-
bation and fresh media applied. The time taken to close the gap created was monitored using a JuLi™ microscope 
over 24 h (PC3) or 96 h (LNCaP) (n = 3).
Invasion. Cells were serum starved for 24 h, harvested and re-suspended in serum-free media. The colla-
gen inserts (ECM551, Merck Millipore, Germany) were rehydrated and 250 µl of cell suspension was applied. 
Serum-containing media (500 µl) was added to the bottom of the well and the inserts were incubated for 24 h 
(PC3) and 48 h (LNCaP) at 37 °C and 5% CO2. The cells that had invaded the collagen layer were subsequently 
stained and imaged according to manufacturer’s instructions (n = 3).
Tumour Metastasis RT2 Profiler PCR Array. RNA (1 µg) was converted to cDNA using the RT2 First 
Strand Kit (Qiagen) and applied to the Tumour Metastasis RT2 Profiler PCR Array according to the manufactur-
er’s instructions. Genes that demonstrated significantly altered expression levels were verified by qRT-PCR anal-
ysis (n = 3). Primers were obtained from PrimerDesign: MMP 3 (NM_002422), MMP10 (NM_002425), MMP13 
(NM_002427), FGFR4 (NM_002011), IL1β (NM_000576), KiSS1 (NM_002256), SERPINE1 (NM_000602), 
CD82 (NM_002231), IGF1 (NM_00111128), MET (NM_000245) and MMP7 (NM_002423).
Immunohistochemistry. Pca Tissue Microarrays (TMAs), were custom built and provided by Wales Cancer 
Bank, Cardiff, UK following successful application to the biobank for the tissue samples to conduct the associated 
study. The Wales Cancer Bank is licensed by the Human Tissue Authority (licence 12107) to store human tissue 
for research, which has been obtained from patients providing informed consent. Wales Cancer Bank holds ethi-
cal approval from Wales Research Ethics Committee 3 to act as a research tissue biobank to both collect and issue 
biomaterials for cancer related research, where successful peer-reviewed applications have been approved. All 
methods applied in this report were therefore carried out in accordance with relevant guidelines and regulations 
in place for Wales Cancer Bank related studies. TMAs were constructed by Wales Cancer Bank from 164 PCa 
specimens with a range of Gleason scores. Three TMAs were generated in total containing: TMA1 – 68 cancer 
and 16 normal samples, TMA2 – 56 cancer and 14 normal samples and TMA3 – 40 cancer and 6 normal samples 
(normal samples were histologically normal tissues taken from patients with PCa). Patient information was pro-
vided in an anonymised fashion, including Gleason score, PSA values, age, death and relapse (Table 2). Formalin 
fixed, paraffin embedded sections were mounted on FLEX IHC slides, baked for 1 h at 60 °C and processed on 
a Benchmark XT automated staining system (Ventana ULTRA). Antigen retrieval was carried out for 32 min-
utes using cell conditioning buffer 1 (CC1), followed by pre-peroxidase inhibitor for 4 minutes at 36 °C. STEAP2 
Primary antibody(1:50, rabbit,IgG, polyclonal, Abcam) was applied for 28 m at 36 °C. OV HQ Universal linker 
containing secondary antibody was applied (8 mins), OV- HPR multimer was applied (8 mins). OV DAB and 
H2O2 was applied (8 mins) before being incubated in copper (4 mins) followed by OV AMP multimer (4–8 mins). 
The slides were then counterstained with Haematoxylin for 8 mins. TMAs were scored by two individuals, blind 
Gleason Score
No. of Tissue 
Samples
Age Range 
(Years)
PSA Range 
(ng/ml)
No. of Deaths/
Relapse
Normal prostate tissue 28 48–75 2.8–19.6 2
6 18 49–71 2.2–19.6 2
3 + 4 = 7 28 49–74 4.5–22.5 3
4 + 3 = 7 10 54–75 2.2–18 1
8 19 48–72 3.1–31.7 6
9 and 10 33 43–84 2.2–160 14
Total 136 43–84 2.2–160 28
Table 2. Patient information relating to the prostate cancer specimens provided by WCB. Number of tissue 
samples available for each STEAP2 analysis, along with age range, PSA range and number of death and/or 
relapse cases for patients falling into each Gleason score category. (“Normal” samples were from histologically 
normal areas of tissue from prostate cancer patients).
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to patient details. To ensure the control tissue used was histologically normal, with no possible infiltration of 
tumour, control cores were carefully evaluated in parallel H&E stained sections of each TMA by a consultant his-
topathologist. Additionally, as multiple sections were cut per TMA block to allow for all test antibodies to be ana-
lysed, H&E sections were generated from the first and last sections to ensure the cores scored were appropriately 
graded by the same consultant histopathologist. Samples with insufficient staining, poor quality of stain, compro-
mised cores (e.g. rolled or partially missing) or lack of tumour cells in the sample were discarded from analysis. 
The test antibodies were optimised using positive control tissue, which was also run alongside all subsequent 
experiments to ensure the staining was appropriate for quality control purposes. Protein analysis was based on the 
intensity of the highest stain observed (scored 0 = none, 1 = low, 2 = medium and 3 = high) and the percentage 
of cells stained with this intensity (scored 0 = none, 1 = 1–25%, 2 = 26–50%. 3 = 51–75% and 4 = 76–100%). The 
final score was then obtained by multiplying the intensity and percentage scores together and were subsequently 
defined as: 0–2 = Low, 3–6 = Medium and 8–12 = High.
Statistical Analysis. Statistical analysis was performed using IBM SPSS Statistics version 22. All compar-
isons to the KD samples were performed using a two-tailed, independent samples t-test. For IHC analysis, the 
following parametric tests were utilised; Pearson test to assess the correlation between STEAP2 and Gleason score 
and one-way ANOVA to determine differences between means. A p-value of <0.05 was considered significant.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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